期刊文献+

Interferon beta(IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway 被引量:2

Interferon beta(IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway
在线阅读 下载PDF
导出
摘要 Multiple sclerosis(MS)is a chronic autoimmune disease of the central nervous system(CNS)characterized by coexisting processes of inflammation,demyelination,axonal neurodegeneration,and gliosis.It is the most common disabling neurological disease in young adulthood. Multiple sclerosis(MS)is a chronic autoimmune disease of the central nervous system(CNS)characterized by coexisting processes of inflammation,demyelination,axonal neurodegeneration,and gliosis.It is the most common disabling neurological disease in young adulthood.
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2015年第12期1932-1933,共2页 中国神经再生研究(英文版)
基金 Dr.Mao-Draayer has served as a consultant and/or received grant support from:Acorda,Bayer Pharmaceutical,Biogen Idec,EMD Serono,Genzyme,Novartis,Questor,Teva Neuroscience and Chugai Pharma Dr.Mao-Draayeris currently supported by grants from NIH NIAID Autoimmune Center of Excellence:UM1-AI110557 NIH NINDS R01-NS080821 the University of Michigan Neurology Department
  • 相关文献

参考文献12

  • 1Aharoni R (2013) The mechanism of action of glatiramer acetate in multiple scle- rosis and beyond. Autoimrnun Rev 12:543-553.
  • 2Arscott WT, Soltys J, Knight I, Mao-Draayer Y (2011) Interferon β-1b directly modulates human neural stem/progenitor cell fate. Brain Res 1413:1-8.
  • 3Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, Nociti V, Tonali PA, Mirabella M (2005) Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand] lmmunol 62:176-182.
  • 4Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, Nociti V, "Ibnali PA, Mirabella M (2006) Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin lnmmnol 118:77-82.
  • 5EI-Behi i1, Dai H, Magalhaes JG, Hwang D, Zhang GX, Rostami A, Ciric B (2014) Committed Tcl7 cells are phenotypically and functionally resistant to the ef- fects of Ik-27. Eur l lmmuno144:3003-3014.
  • 6Fitzgerald DC, Fonseca-Kelly Z, Cullimore ML, Safabakhsh P, Saris CJ, Zhang GX, Rostami A (2013) Independent and interdependent immunoregulatory ef/cts of IL-27, IFN-, and IL-10 in the suppression of human Thl7 cells and murine experimental autoimmuue encephalomyelitis. J Immmaol190:3225-3234.
  • 7Hamamcioglu K, Reder KI (2007). Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 13:459-470.
  • 8Hirsch M, Knight 1, Tobita M, Soltys J, Panitch H, Mao-Draayer Y (2009) The effect of interferon-beta on mouse neural progenitor cell survival and differentiation. Biochem Biophys Res Commun 388:181 - 186.
  • 9Kochanowski J, Uchman D, Litwiniuk A, Kalisz M, Wolinska-Witort E, Martynska L, Baranowska B, Bik W (2015) Assessment of plasma brain-derived neurotrophic factor (BDNF), activity-dependent neurotrophin protein (ADNP) and vasoac- rive intestinal peptide (VIP) concentrations in treatment-naive humans with multiple sclerosis. Neuro Endocrinol Lett 36:148-152.
  • 10Mascanffoni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, Wu Y, Mayo L, Ben-Hamo R, Et'roni S, Kuchroo VK, Robson SC, Quintana FI (2013) 1L-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expres- sion of the immunoregulatory molecule CD39. Nat lmmunol 14:1054-1063.

同被引文献26

引证文献2

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部